A Single Center Real-world Study of Donafenib in the Treatment of Hepatocellular Carcinoma in Routine Clinical Practice
This trial is a single center observational real-world study. It is planned to include 300 patients with unresectable hepatocellular carcinoma (uHCC) treated with Donafenib. The purpose of the study was to observe the effectiveness and safety of Donafenib in the real world.
Donafenib|Hepatocellular Carcinoma
Incidence of adverse events and serious adverse events., Incidence of adverse events and serious adverse events., an average of 1.5 year.
Objective response rate (ORR), According to RECIST v1.1 and mRECIST to evaluate the proportion of patients with complete response(CR) and partial response(PR) in the total number of patients., an average of 1 year.|Duration of remission (DoR), Time from the date of first confirmed CR or PR to the occurrence of disease progression., an average of 1 year.|Disease control rate (DCR), According to RECIST v1.1 and mRECIST to evaluate the proportion of patients with CR, PR and stable disease(SD) in the total number of patients., an average of 1 year|Progression-free survival(PFS), PFS refers to the time from the date of enrollment to tumor progression or death from any cause., an average of 1 year|overall survival(OS), The time from the date of enrollment to the date of death from any cause., an average of 1 year
This trial is a single center observational real-world study. It is planned to include 300 patients with unresectable hepatocellular carcinoma (uHCC) treated with Donafenib. The purpose of the study was to observe the effectiveness and safety of Donafenib in the real world.